Bristol Myers Squibb said Tuesday that an oral drug designed to treat psoriasis differently from currently approved medicines demonstrated superiority to placebo and a competing drug from Amgen.
Bristol Myers Squibb said Tuesday that an oral drug designed to treat psoriasis differently from currently approved medicines demonstrated superiority to placebo and a competing drug from Amgen.
Copyright © 2023 Biotech Networks, LLC